Cipla to Recall Lanreotide Injection in US, Temporary Supply Disruption Expected
New Delhi: Cipla Limited has announced that its wholly owned subsidiary Cipla USA Inc. will initiate a recall of certain unexpired batches of Lanreotide Injection in the United States, which will result in a temporary lack of supply of the product in the market.
The company disclosed the development to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the disclosure, the decision to initiate the recall follows discussions with Pharmathen International S.A.. As part of the action, Cipla USA Inc. will recall the remaining unexpired batches of Lanreotide Injection currently available in the market.
Cipla noted that the recall will lead to a temporary shortage of the product in the US market until frther updates regarding supply are communicated.
The latest update follows the company’s earlier communications to stock exchanges dated January 7, January 14, and February 21, 2026 regarding the matter.
According to Cipla Limited’s regulatory filing, the company has informed the relevant stock exchanges about the recall decision and its potential impact on product availability.
